HOWL
Werewolf Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.97
+2.38%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +66.8%
- EBIT
- +65.0%
- EPS
- +55.2%
- Free cash flow
- +50.5%
- Operating cash flow
- +50.4%
Forward estimates
Based on analyst estimates
- Revenue
- +187.2%
- EBITDA
- —
- EPS
- -84.9%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +15.8%
- EBIT
- +17.6%
- Net income
- +13.7%
- EPS
- +19.0%
- Free cash flow
- -6.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026